Illumina Stock Earnings Reports

Illumina reported a strong Q1 2026: revenue of $1.09B (up 4.8% YoY), non-GAAP EPS of $1.15 (≈19% YoY), and gross margin and operating margin expansion above guidance. Key drivers were robust NovaSeq X instrument placements (over 80 in the quarter), strong clinical consumables demand (clinical sequencing consumables ex-China grew ~20% for the second consecutive quarter), and the close of the SomaLogic acquisition. Management raised 2026 guidance modestly (revenue now $4.52B–$4.62B; non-GAAP EPS $5.15–$5.30) and increased expected operating margins (now ~23.4%–23.6%). They remain supply-constrained on NovaSeq X but are investing to scale production; management expects continued clinical momentum while research/applied markets stay cautious given funding uncertainty. Cash flow was strong ($289M operating cash), free cash flow $251M; Illumina repurchased shares in Q1 and the Board authorized an additional $1.5B buyback. Management reiterated a multi-year thesis: continued NovaSeq X adoption, product innovation (TruPath, spatial transcriptomics, new X flow cells), expanding data/AI initiatives (BioInsight, Billion Cell Atlas), and progress toward 2027 targets of high-single-digit revenue growth, margin expansion, and double-digit EPS growth.